Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1465-1469

  Masuda, Takeshi ^a   Hattori, Noboru ^a   Hamada, Akinobu ^b   Iwamoto, Hiroshi ^a   Ohshimo, Shinichiro ^a   Kanehara, Masashi ^a   Ishikawa, Nobuhisa ^a   Fujitaka, Kazunori ^a   Haruta, Yoshinori ^a   Murai, Hiroshi ^a   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cerebrospinal fluid; Erlotinib; Gefitinib; Leptomeningeal metastases; Non small cell lung cancer

Indexed keywords

ERLOTINIB; GEFITINIB;

ADULT; ARTICLE; CARCINOMA CELL; CASE REPORT; CYTOLOGY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDERMAL GROWTH FACTOR GENE; EXON; GENE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; LEPTOMENINGEAL METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; NEUROLOGIC DISEASE; PERFORMANCE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; DRUG SUBSTITUTION; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79959614287     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1555-6     Document Type: Article

References (23)

1. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY (2005) Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75:85-99 (Pubitemid 41548681)
2. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103-119 (Pubitemid 29353669)
3. Ceresoli GL, Reni M, Chiesa G, Carretta A, Schipani S, Passoni P, Bolognesi A, Zannini P, Villa E (2002) Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 95:605-612 (Pubitemid 34810187)
4. O'Meara WP, Borkar SA, Stambuk HE, Lymberis SC (2007) Leptomeningeal metastasis. Curr Probl Cancer 31:367-424
5. Chamberlain MC, Kormanik P (1998) Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55:506-512 (Pubitemid 28182696)
6. Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4:1415-1419
7. Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80-84
8. Fukuhara T, Saijo Y, Sakakibara T, Inoue A, Morikawa N, Kanamori M, Nakashima I, Nukiwa T (2008) Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med 214:359-363 (Pubitemid 351761054)
9. Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS (2005) Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 50:265-269
10. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB (2010) High dose weekly Erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99:283-286
11. Nagai Y, Miyazawa H, Huqun TanakaT, Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M, Hagiwara K (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276-7282 (Pubitemid 41161259)
12. Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A (2003) Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci 796:181-188 (Pubitemid 38352722)
13. Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M (2010) Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 5:950-955
14. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Janne PA, Johnson BE (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517-4520 (Pubitemid 46630993)
15. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T (2005) Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 44:1165-1177 (Pubitemid 41483701)
16. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, Lum BL (2006) Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 46:282-290 (Pubitemid 43260315)
17. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279 (Pubitemid 32591445)
18. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK (2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240-2250 (Pubitemid 34441651)
19. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
20. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P (1997) Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848 (Pubitemid 27468992)
21. Kancha RK, von Bubnoff N, Peschel C, Duyster J (2009) Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 15:460-467
22. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R (2005) Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11:6414-6421 (Pubitemid 41338977)
23. Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD (2006) Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24:291-297